Latest News

Novozymes bags Organobalance

Enzyme fermentation at Novozymes' pilot plant, in Bagsværd, Denmark © Novozymes


Denmark’s Novozymes has acquired microbial research company Organobalance GmbH. The German company owns a large collection of microbial strains, some of which date back to the 1920s, and has strong capabilities in microbial screening and assay technology.

Germany-based Organobalance specializes in developing natural microbial solutions for customers and partners across a number of industries including food, feed, and animal health. Now, the company with a staff of 29  has been bought up by Danish industrial enzymes and microorganism expert Novozymes for an undisclosed amount.

“The experience of Organobalance’s founding scientists, and the company’s know-how, immediately strengthen Novozymes’ existing capabilities within microbial technologies,” says Sebastian Søderberg, Vice President for New Business Development, Incubation & Acquisitions at Novozymes. “Organobalance will advance our understanding to develop new, sustainable solutions across industries, and provide us with additional commercial opportunities.”

Organobalance co-founder Christine Lang will continue as General Manager. Lang commented: “By becoming part of Novozymes, we will have access to a global R&D network and an extensive infrastructure to bring products to market – a clear advantage for us and our customers."

New antibiotics on the block

For developers of antimicrobial resistance breakers, the meeting organized by the European Society of Clinical Microbiology and Infectious Diseases...

Sphingotec raises €20m in growth equity financing

Sphingotec announced it will primarily use the proceeds to roll out the fully automated IB 10 point-of-care (POC) platform for testing of a broad...

FDA greenlights Shire’s HAE mAB Takhzyro

The antibody, baged by Shire in 2016 by the US$ 6.5bn Dyax buy out, targets the plasma protein kallikrein, which leads to type I-III HAE by...

First migraine prevention drug hits EU market

For the first time, migraine patients who experience four or more migraine days per month have access to a preventative treatment in the EU....

Pharming receives complete response letter from FDA

In 2017, Pharming filed an sBLA to the FDA in order to expand the label of its recombinantly produced C1 esterase inhibitor Ruconest to prophylaxis...

EMA recommends four biologicals for market

The EMA's has extended its review for a MAA filed by Bristol-Myers Squibb for its PD1/CTLA4 checkpoint inhibitor combo Nivolumab/Ipilimumab as...

Getting ready for Brexit

Hard Brexit or soft Brexit – however the UK will leave the European Union next year, the process is sure to cause some disruption. Now, pharma...